Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

1.

The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis.

van Dongen CJ, Vink R, Hutten BA, Büller HR, Prins MH.

Arch Intern Med. 2003 Jun 9;163(11):1285-93.

PMID:
12796064
[PubMed - indexed for MEDLINE]
2.

Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.

Hutten BA, Prins MH.

Cochrane Database Syst Rev. 2000;(3):CD001367. Review.

PMID:
10908494
[PubMed - indexed for MEDLINE]
3.

Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.

Hutten BA, Prins MH.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001367. Review.

PMID:
16437432
[PubMed - indexed for MEDLINE]
4.

Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

van Der Heijden JF, Hutten BA, Büller HR, Prins MH.

Cochrane Database Syst Rev. 2000;(4):CD002001. Review. Update in: Cochrane Database Syst Rev. 2002;(1):CD002001.

PMID:
11034739
[PubMed - indexed for MEDLINE]
5.

Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalà M, Papaldo P, Fabi A, Ciccarese M, Cuppone F, Cecere FL, Nuzzo C, Terzoli E, Cognetti F.

Chest. 2006 Dec;130(6):1808-16.

PMID:
17167001
[PubMed - indexed for MEDLINE]
6.
7.

Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.

Schulman S, Lindmarker P.

N Engl J Med. 2000 Jun 29;342(26):1953-8.

PMID:
10874063
[PubMed - indexed for MEDLINE]
Free Article
8.

Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.

McRae S, Tran H, Schulman S, Ginsberg J, Kearon C.

Lancet. 2006 Jul 29;368(9533):371-8. Review.

PMID:
16876665
[PubMed - indexed for MEDLINE]
9.

Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

van der Heijden JF, Hutten BA, Büller HR, Prins MH.

Cochrane Database Syst Rev. 2002;(1):CD002001. Review. Update in: Cochrane Database Syst Rev. 2012;10:CD002001.

PMID:
11869618
[PubMed - indexed for MEDLINE]
10.
11.

Recurrent thromboembolism after treatment with vitamin K antagonists.

van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH.

Arch Intern Med. 2003 Dec 8-22;163(22):2793. No abstract available.

PMID:
14662641
[PubMed - indexed for MEDLINE]
12.

Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.

Schulman S, Lindmarker P, Holmström M, Lärfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M.

J Thromb Haemost. 2006 Apr;4(4):734-42.

PMID:
16634738
[PubMed - indexed for MEDLINE]
13.

Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature.

Streiff MB, Segal JB, Tamariz LJ, Jenckes MW, Bolger DT, Eng J, Krishnan JA, Bass EB.

Am J Hematol. 2006 Sep;81(9):684-91. Review.

PMID:
16838335
[PubMed - indexed for MEDLINE]
14.

Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.

Louzada ML, Majeed H, Wells PS.

Thromb Res. 2009 Apr;123(6):837-44. doi: 10.1016/j.thromres.2008.09.002. Epub 2008 Nov 1.

PMID:
18977517
[PubMed - indexed for MEDLINE]
15.

Long-term management of patients after venous thromboembolism.

Kearon C.

Circulation. 2004 Aug 31;110(9 Suppl 1):I10-8. Review.

PMID:
15339876
[PubMed - indexed for MEDLINE]
Free Article
16.

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A.

Haematologica. 2007 Feb;92(2):199-205.

PMID:
17296569
[PubMed - indexed for MEDLINE]
Free Article
17.

Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials.

Pinede L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel JP.

J Intern Med. 2000 May;247(5):553-62.

PMID:
10809994
[PubMed - indexed for MEDLINE]
18.
19.

[Therapy and secondary prevention of venous thromboembolism with vitamin K antagonists].

Bauersachs RM.

Internist (Berl). 2003 Dec;44(12):1491-9. Review. German.

PMID:
14689191
[PubMed - indexed for MEDLINE]
20.

Duration of anticoagulation therapy for venous thromboembolism.

Bounameaux H, Perrier A.

Hematology Am Soc Hematol Educ Program. 2008:252-8. doi: 10.1182/asheducation-2008.1.252.

PMID:
19074092
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk